Nanexa AB NANEXA
OMXSTO · Sweden · Health Technology
SEK 10.00+0.04 (+0.40%)
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.
It was reported on September 25 that Novo Nordisk A/S (NYSE:NVO) has entered into an exclusive global license and collaboration agreement with Swedish drug delivery platform company Nanexa AB. The partnership centers on leveraging Nanexa’s proprietary PharmaShell technology platform across up to five development programs focused on obesity, type 2 diabetes, and other cardiometabolic indications. […]
Novo has meanwhile been busy bolstering its pipeline amid a target to launch more than five multi-blockbusters by 2030.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.